Kontafarma China Holdings (HKSE:01312) Gross-Profit-to-Asset % : 25.21% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Kontafarma China Holdings's annualized Gross Profit for the quarter that ended in Dec. 2023 was HK$448.0 Mil. Kontafarma China Holdings's average Total Assets over the quarter that ended in Dec. 2023 was HK$1,777.4 Mil. Therefore, Kontafarma China Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 25.21%.

Kontafarma China Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Kontafarma China Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kontafarma China Holdings Gross-Profit-to-Asset % Chart

Kontafarma China Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

13.55

16.99

15.53

21.64

24.50

Kontafarma China Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															16.56	21.32	20.85	25.05	25.21

Competitive Comparison of Kontafarma China Holdings's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kontafarma China Holdings's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's Gross-Profit-to-Asset % falls into.

Kontafarma China Holdings Gross-Profit-to-Asset % Calculation

Kontafarma China Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	471.292	/	( (2120.443	+	1727.335)	/ 2 )
	=	471.292	/	1923.889
	=	24.50 %

Kontafarma China Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	448.028	/	( (1827.373	+	1727.335)	/ 2 )
	=	448.028	/	1777.354
	=	25.21 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Kontafarma China Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kontafarma China Holdings (HKSE:01312) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » Gross-Profit-to-Asset %

Traded in Other Exchanges

N/A

Address

30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG

Website

https://www.kontafarma.com.hk

Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.

Executives

Ning Bo Bao Shui Qu San Jin Guo Tou Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Shan Xi Jiao Tong Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Shan Xi Jian She Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Shan Xi Sheng Ren Min Zheng Fu Guo You Zi Chan Jian Du Guan Li Wei Yuan Hui	2201 Interest of corporation controlled by you
Shan Xi Sheng Gao Su Gong Lu Ji Tuan You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you
Shan Xi Sheng Guo You Zi Ben Yun Ying You Xian Gong Si Qian Cheng Shan Xi Sheng Guo You Zi Ben Tou Z	2201 Interest of corporation controlled by you
China Health Management Investment Limited	2101 Beneficial owner
Waranty Assets Management (hk) Limited	2201 Interest of corporation controlled by you
Shen Zhen Shi Hua Rong Tai Zi Chan Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Resuccess Investments Limited
Thtf Energy-saving Holdings Limited

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines